Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONKO-006: Gemcitabine + sorafenib in R1-resected pancreatic cancer
DRKS00000242Phase 2Active, not recruiting
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pancreatic cancer (PC) comparing Gemcitabine + sorafenib with Gemcitabine + placebo (2 arms). Started Mar 2010; status: active, not recruiting.
02
Drugs
sorafenibgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on DRKS00000242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00000242.